MeiraGTx

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicine company committed to harnessing the full potential of genetic therapies for both rare and prevalent diseases. The company has built a broad pipeline with four late-stage clinical programs, each utilizing local delivery of small doses to achieve disease-modifying effects in inherited and more common conditions affecting the eye, salivary glands, and neurological systems.

What sets MeiraGTx apart is its comprehensive end-to-end manufacturing ecosystem, which the company has developed over nine years based on more than 20 different viral vectors with leading yield and quality parameters. The company operates GMP-licensed manufacturing and QC facilities in the United States, United Kingdom, and Ireland, making it one of the most comprehensive genetic medicine manufacturing operations in the industry.

MeiraGTx is pioneering transformative technologies including its novel riboswitch gene regulation platform, which allows unprecedented spatial and temporal control of transgene expression through oral small molecules. This platform enables the regulated in vivo delivery of metabolic peptides including GLP-1, GIP, Glucagon, Amylin, PYY and Leptin, as well as cell therapies for liquid and solid tumors and autoimmune diseases. The company is uniquely positioned to bring genetic medicine to common diseases, expanding access in some of the largest therapeutic areas where unmet medical need remains high.